Genetic Vaccines and Therapy (Genet Vaccine Ther )

Publisher: BioMed Central Ltd

Description

Genetic Vaccines and Therapy is an Open Access, peer-reviewed, online journal dedicated to applying new knowledge about genetics in treating human disease. Genetic Vaccines and Therapy is aimed at researchers, clinicians and biotechnologists, worldwide, in the field of gene-based therapy and drug delivery. Examples of current topics of interest include: development of new biocompatible delivery materials, design of effective and safe vectors, exploration of new strategies for targeting drugs, and application of siRNA gene silencing to specific disease therapies. The field of genetic therapy is just beginning to see an increase in interest and applicability in the pharmaceutical and biotechnology community, and we have positioned this journal to meet the needs of workers in this new and highly promising area. Our goal in creating this new journal was to provide a platform for materials scientists and gene-delivery specialists, to come together with researchers and clinicians to explore new ways of combating disease by using DNA-based therapeutic agents. Traditional gene therapy has been aimed primarily at correcting hereditary problems; our focus is more broad, including the use of gene expression vectors for the endogenous production of factors designed to interfere with a wide range of diseases, including: asthma, viral infection, cancer and Alzheimer's disease. We hope that our efforts will be rewarded by an increased awareness of the tremendous medical potential of gene-based therapeutics, and an accelerated application of these materials to the prevention and treatment of a host of diseases.

  • Impact factor
    2.10
  • 5-year impact
    0.00
  • Cited half-life
    0.00
  • Immediacy index
    0.00
  • Eigenfactor
    0.00
  • Article influence
    0.00
  • Website
    Genetic Vaccines and Therapy website
  • ISSN
    1479-0556
  • OCLC
    53186143
  • Material type
    Document, Periodical, Internet resource
  • Document type
    Internet Resource, Computer File, Journal / Magazine / Newspaper

Publications in this journal

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This article [Jafri et al, Genetic Vaccines and Therapy, 2012 10:4] is retracted by the Editor because the peer review process was compromised due to a referee's undeclared conflict of interest. Based on post-publication peer review the Editor cannot trust the veracity of the findings. We apologize to all affected parties.
    Genetic Vaccines and Therapy 10/2012; 10(1):10.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Peptide/DNA complexes have great potential as non-viral methods for gene delivery. Despite promising results for peptide-mediated gene delivery technology, an effective systemic peptide-based gene delivery system has not yet been developed. This study used pCMV-Luc as a model gene to investigate the biodistribution and the in vivo efficacy of arginine peptide-mediated gene delivery by polymerase chain reaction (PCR). Plasmid DNA was detected in all organs tested 1 h after intraperitoneal administration of arginine/DNA complexes, indicating that the arginine/DNA complexes disseminated widely through the body. The plasmid was primarily detected in the spleen, kidney, and diaphragm 24 h post administration. The mRNA expression of plasmid DNA was noted in the spleen, kidney, and diaphragm for up to 2 weeks, and in the other major organs, for at least 1 week. Blood clearance studies showed that injected DNA was found in the blood as long as 6 h after injection. Taken together, our results demonstrated that arginine/DNA complexes are stable in blood and are effective for in vivo gene delivery. These findings suggest that intraperitoneal administration of arginine/DNA complexes is a promising tool in gene therapy.
    Genetic Vaccines and Therapy 08/2011; 9:13.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Antigen presentation by non professional antigen presenting cells (APC) can lead to anergy. In genetic vaccines, targeting the macrophages and APC for efficient antigen presentation might lead to balanced immune response. One such approach is to incorporate APC specific promoter in the vector to be used. Three promoters known to be active in macrophage were selected and cloned in mammalian expressing vector (pAcGFP1-N1) to reconstruct (pAcGFP-MS), (pAcGFP-EMR) and (pAcGFP-B5I) with macrosialin, EmrI and Beta-5 Integrin promoters respectively. As a positive control (pAcGFP-CMV) was used with CMV promoter and promoterless vector (pAcGFP-NIX) which served as a negative control. GFP gene was used as readout under the control of each of the promoter. The expression of GFP was analyzed on macrophage and non-macrophage cell lines using Flow cytometry and qRT-PCR with TaqMan probe chemistries. All the promoters in question were dominant to macrophage lineage cell lines as observed by fluorescence, Western blot and quantitative RT-PCR. The activity of macrosialin was significantly higher than other macrophage promoters. CMV promoter showed 1.83 times higher activity in macrophage cell lines. The expression of GFP driven by macrosialin promoter after 24 hours was 4.40 times higher in macrophage derived cell lines in comparison with non macrophage cell lines. Based on this study, macrosialin promoter can be utilized for targeting macrophage dominant expression. In vivo study needs to be carried out for its utility as a vaccine candidate.
    Genetic Vaccines and Therapy 06/2011; 9(1):10.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the selective killing efficacy of the double suicide genes driven by KDR promoter. A double suicide gene system with the KDR promoter, pcDNA3-KDRp-CDglyTK, was constructed and transfected into lung cancer cell lines L9981 and NL9980, and human hepatocellular carcinoma cell line HepG2. The efficiency and specificity of the double suicide gene system were assayed by in vitro cellular proliferation and apoptosis, as well as in vivo xenograft studies. The transgenic CD and TK genes were only expressed in L9981 and NL9980 but not in HepG2 cells. Pre-treating transfected cells with 5-Fc and GCV significantly reduced proliferation, enhanced apoptosis in L9981 and NL9980 but not in HepG2 cells. The tumor formed by L9981 and NL9980 cells with the double suicide gene system was much smaller in vivo. Tumor targeted expression of CDglyTK gene driven by KDR promotor represents a novel strategy for effective gene therapy of tumor with intrinsic KDR.
    Genetic Vaccines and Therapy 03/2011; 9:6.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Both adenoviral and lentiviral vectors have been successfully used to induce bone repair by over-expression of human bone morphogenetic protein 2 (BMP-2) in primary rat bone marrow stromal cells in pre-clinical models of ex vivo regional gene therapy. Despite being a very efficient means of gene delivery, there are potential safety concerns that may limit the adaptation of these viral vectors for clinical use in humans. Recombinant adeno-associated viral (rAAV) vector is a promising viral vector without known pathogenicity in humans and has the potential to be an effective gene delivery vehicle to enhance bone repair. In this study, we investigated gene transfer in rat and human bone marrow stromal cells in order to evaluate the effectiveness of the self-complementary AAV vector (scAAV) system, which has higher efficiency than the single-stranded AAV vector (ssAAV) due to its unique viral genome that bypasses the rate-limiting conversion step necessary in ssAAV. Self-complementaryAAV2 encoding GFP and BMP-2 (scAAV2-GFP and scAAV2-BMP-2) were used to transduce human and rat bone marrow stromal cells in vitro, and subsequently the levels of GFP and BMP-2 expression were assessed 48 hours after treatment. In parallel experiments, adenoviral and lentiviral vector mediated over-expression of GFP and BMP-2 were used for comparison. Our results demonstrate that the scAAV2 is not capable of inducing significant transgene expression in human and rat bone marrow stromal cells, which may be associated with its unique tropism. In developing ex vivo gene therapy regimens, the ability of a vector to induce the appropriate level of transgene expression needs to be evaluated for each cell type and vector used.
    Genetic Vaccines and Therapy 02/2011; 9:4.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: RNAi gene therapies for HIV-1 will likely need to employ multiple shRNAs to counter resistant strains. We evaluated 3 shRNA co-expression methods to determine their suitability for present use; multiple expression vectors, multiple expression cassettes and single transcripts comprised of several dsRNA units (aka domains) with each being designed to a different target. Though the multiple vector strategy was effective with 2 shRNAs, the increasing number of vectors required is a major shortcoming. With single transcript configurations we only saw adequate activity from 1 of 10 variants tested, the variants being comprised of 2 - 3 different target domains. Whilst single transcript configurations have the most advantages on paper, these configurations can not yet be rapidly and reliably re-configured for new targets. However, our multiple cassette combinations of 2, 3 and 4 (29 bp) shRNAs were all successful, with suitable activity maintained in all positions and net activities comparable to that of the corresponding single shRNAs. We conclude that the multiple cassette strategy is the most suitably developed for present use as it is easy to design, assemble, is directly compatible with pre-existing shRNA and can be easily expanded.
    Genetic Vaccines and Therapy 01/2011; 9(1):9.